Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01750281 · ClinicalTrials.gov registry record · Phase 2
Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
A Phase 2 study of Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 212
- Enrollment target
- 20
- Study locations
NCT01750281 is a Phase 2 study of Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV that has completed, run by AstraZeneca. The registered enrollment target is 212 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT01750281, a Phase 2 study of Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 212 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to treat patients with locally advanced or metastatic NSCLC with a combination therapy of selumetinib and two different doses of docetaxel 75mg/m2 or 60 mg/m2 vs placebo and compare how well each dose affects how their cancer responds. It will also help us to understand the tolerability profile of the different dosing regimens in these patients
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Docetaxel 75 mg/m2
- DRUG Docetaxel 60 mg/m2
- DRUG Selumetinib 75 mg
Study Locations (20)
Other
- Research Site - Barretos
- Research Site - Brasília
- Research Site - Ijuí
- Research Site - Porto Alegre
- Research Site - Porto Alegre
- Research Site - Porto Alegre
- Research Site - Santo André
New York
- Research Site - Mineola
- Research Site - New York
- Research Site - New York
Pennsylvania
- Research Site - Hershey
- Research Site - Philadelphia
California
- Research Site - Santa Monica
Colorado
- Research Site - Aurora
Florida
- Research Site - Hollywood
Georgia
- Research Site - Atlanta
Illinois
- Research Site - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2012-12-18 |
| Est. Completion | 2022-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01750281
The ClinicalTrials.gov registry entry for NCT01750281 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01750281 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01750281 about?
NCT01750281 is a clinical study titled "Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.". The purpose of this study is to treat patients with locally advanced or metastatic NSCLC with a combination therapy of selumetinib and two different doses of docetaxel 75mg/m2 or 60 mg/m2 vs placebo and compare how well each dose affects how their cancer responds. It will also help us to understand ...
What is the current status of trial NCT01750281?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 212 participants. The study started on 2012-12-18. Estimated completion is 2022-10-31.
What conditions does trial NCT01750281 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV.
What interventions are being tested in trial NCT01750281?
The interventions under investigation include: Placebo (DRUG), Docetaxel 75 mg/m2 (DRUG), Docetaxel 60 mg/m2 (DRUG), Selumetinib 75 mg (DRUG).
Who is sponsoring clinical trial NCT01750281?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01750281 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.